Bioavailability of Aronia Melanocarpa
Launched by MAASTRICHT UNIVERSITY MEDICAL CENTER · Mar 11, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well the body absorbs and processes a drink made from Aronia Melanocarpa, also known as black chokeberry. The researchers want to understand how this supplement affects healthy adults, both young (ages 18-35) and older (ages 55-75). Participants in the study will drink a special Aronia Melanocarpa extract, and then the team will closely monitor their blood, urine, and stool to see how the body handles it.
To participate, individuals need to be generally healthy, with a body mass index (BMI) between 18 and 35, and stable blood pressure levels. They should not have serious medical conditions like diabetes or heart disease, and they must be willing to refrain from donating blood for a certain time before, during, and after the study. Participants can expect to visit the study site for tests and sampling, and they will play an important role in helping researchers learn more about the potential benefits of Aronia Melanocarpa.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • BMI between 18-35 kg/m2
- • Systolic blood pressure \< 160 mmHg and diastolic blood pressure \< 100 mmHg
- • Stable body weight (weight gain or loss \< 3 kg in the past three months)
- • Willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeks after completion of the study
- Exclusion Criteria:
- • Smoking or smoking cessation \< 12 months
- • Severe medical conditions, including asthma, kidney failure, auto-inflammatory diseases, rheumatoid arthritis, diabetes mellitus, cardiovascular disease, gastrointestinal disorders such as Crohn's disease, colitis
- • Use of dietary supplements or medication affecting the main outcomes of the study (e.g. affecting gut metabolism, blood pressure medication)
- • Use of an investigational product within another biomedical intervention trial within the previous month
- • Abuse of drugs
- • More than 3 alcoholic consumptions per day
- • Known pregnancy or lactation
- • Known allergy to study product
- • Difficult venepuncture
About Maastricht University Medical Center
Maastricht University Medical Center (MUMC+) is a leading academic medical center in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, MUMC+ integrates cutting-edge scientific inquiry with clinical practice, focusing on a wide range of medical disciplines. The center emphasizes collaboration among multidisciplinary teams, fostering an environment that promotes excellence in patient care and the translation of research findings into clinical applications. MUMC+ is dedicated to improving health outcomes and enhancing quality of life through rigorous clinical investigations and the development of novel therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Maastricht, , Netherlands
Patients applied
Trial Officials
Jogchum Plat, Prof
Principal Investigator
Maastricht University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported